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As research into micro RNA (miRNA) spe-
ciation, complexity, and biological activ-
ity progresses, it is becoming clear that
a selective subset of all so far char-
acterized miRNAs utilized by human
cells and tissues is under the transcrip-
tional control of the pro-inflammatory
and immune system-linked transcrip-
tion factor NF-κB (Sen and Baltimore,
1986; Lukiw and Bazan, 1998; Taganov
et al., 2006; Lukiw, 2007, 2012a,b,c;
Bazzoni et al., 2009; Ma et al., 2011;
Boldin and Baltimore, 2012; Cremer
et al., 2012; Li et al., 2012; Lukiw and
Alexandrov, 2012; Zhao et al., 2013).
The inducible up-regulation of NF-κB-
sensitive miRNAs is by virtue of single,
and often multiple, NF-κB-DNA bind-
ing recognition sites in the regulatory
regions of miRNA-containing genes that
drive RNA polymerase II-mediated tran-
scription of pre-miRNA species (Ambros,
2004; Taganov et al., 2006; Baltimore et al.,
2008; Cui et al., 2010; Guo et al., 2010;
Bredy et al., 2011; Lukiw, 2012a). In
neurodegenerative disease research, stress-
triggered up-regulation of these NF-κB-
induced miRNAs appear to be playing
pathogenic roles in the down-regulation of
brain-essential messenger RNAs (mRNA),
and the initiation and propagation of
pathological gene expression programs
that are, for example, characteristic of
the Alzheimer’s disease (AD) process
(Figure 1). NF-κB-mediated up-regulated
miRNAs and down-regulated mRNA tar-
gets thereby form a highly integrated,
pathogenic NF-κB-miRNA-mRNA signal-
ing network that can explain much of the
observed neuropathology in AD, includ-
ing deficits in phagocytosis (Niemitz,
2012; Zhao et al., 2013), NF-κB-mediated
innate-immune signaling and chronic
inflammation (Cui et al., 2010; Heneka
et al., 2010; Lukiw and Bazan, 2010;
Lukiw et al., 2012), impairments in
neurotransmitter packaging and release,
neurotrophism and amyloidogenesis (Xu
et al., 2009; Lukiw, 2012a,b,c). Under
homeostatic conditions, NF-κB activation
involves a coordinated, sequential, and
self-limiting sequence of events controlled
by positive and negative regulatory mech-
anisms, however, this does not appear to
be the case in early, moderate or especially
advanced stages of sporadic AD. In spo-
radic AD, once initiated, NF-κB-mediated
disruption of homeostatic gene expression
can be self-perpetuating due, in part, to
the chronic re-activation of NF-κB activ-
ities via up-regulation of interleukin-1β
receptor associated kinase-2 (IRAK-2) sig-
naling pathways (Cui et al., 2010). Selective
inhibition of the actions of NF-κB and
specific NF-κB-sensitive miRNAs there-
fore seems a plausible therapeutic strat-
egy towards neutralizing their combined
effects in sporadic AD, and related pro-
gressive, age-related neurological diseases
with an innate-immune and inflammatory
component.
The brain-ubiquitous transcription
factor NF-κB comprises a family of
heterodimeric DNA-binding proteins,
for example the relatively common
p50–p65 complex, that normally reside
in a “resting state” in the cytoplasm
(Sen and Baltimore, 1986; Lukiw and
Bazan, 1998; Mattson and Camandola,
2001; Yamamoto and Gaynor, 2001;
Lukiw, 2012a,b). In general, cytoplasmic
NF-κB activation is stimulated via a wide
array of physiological stressors includ-
ing ionizing radiation, viral infection,
neurotoxic metals, elevations in reac-
tive oxygen species (ROS), inflammatory
cytokines and chemokines, Aβ42 peptides,
hypoxia, and other forms of physiologi-
cal stress (Baltimore et al., 2008; Pogue
et al., 2009, 2011; Boldin and Baltimore,
2012). This activation is largely medi-
ated by the serine- phosphorylation of
a family of NF-κB inhibitory subunits,
non-covalently bound to the NF-κB het-
erodimer, and collectively known as the
inhibitors of kappaB (IκB). IκB phos-
phorylation is followed, in turn, by IκB
degeneration, in part through cooper-
ation with NF-κB essential modulator
(NEMO) proteins (Baltimore et al., 2008;
Shifera, 2010). NF-κB heterodimers next
translocate to the nucleus to target bind-
ing sites homologous to the canonical
DNA sequence 5′-GGGACTTTCC-3′
in the regulatory regions of NF-κB-
sensitive genes (Meffert and Baltimore,
2005; Wong et al., 2011). Ever since
NF-κB’s original description in 1986
several hundred NF-κB inhibitors, both
natural and synthetic, have been devel-
oped to inhibit NF-κB-activation in this
complex signaling network (Sen and
Baltimore, 1986; Mattson and Camandola,
2001; Aggarwal and Shishodia, 2004;
Meffert and Baltimore, 2005; Gilmore and
Herscovitch, 2006; Nam, 2006; Gilmore
and Garbati, 2011). Indeed, inhibition of
NF-κB can involve multifaceted aspects of
NF-κB activation via blocking of NF-κB
signaling at various control points, from
inhibition of the kinases that phospho-
rylate IκB (thus preventing activation of
NF-κB), to the deacetylation of the NF-κB
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FIGURE 1 | (A) In recent experiments human primary neuronal-glial (HNG)
cells were treated with an AD-relevant, NF-κB-inducing cocktail of amyloid
beta 42 (Aβ42) and interleukin-1beta (IL-1β), and inducible miRNAs were
analyzed using miRNA arrays (Lukiw, 2012a). Confirmation of miRNA
induction and NF-κB sensitivity was obtained (1) using LED-Northern dot blot
and/or RT-PCR analysis; (2) by inhibition of this induction using specific NF-κB
inhibitors CAPE, CAY10512, and PDTC and (3) by bioinformatics analysis of
functional NF-κB binding sites in the promoters of the genes that encode
these inducible miRNAs (Lukiw et al., 2008; Cui et al., 2010; Lukiw, 2012a).
A small family of 5 miRNAs—miRNA-9, miRNA-34a, miRNA-125b,
miRNA-146a, and miRNA-155—appear to be up-regulated in high quality total
RNA isolated from short post-mortem AD brains; note that hsa-miR-128 and
miR-25 are variably up-regulated; N = 6; (B) These findings in part define a
highly interactive network of NF-κB-sensitive, up-regulated miRNAs in
stressed human brain cells and AD hippocampus that can explain much of
the observed neuropathology in AD including deficits in phagocytosis
(TREM2), innate-immune signaling and chronic inflammation (IkBKG, CFH,
IRAK-1, and IRAK-2), impairments in neurotransmitter packaging and release
(SYN-2), neurotrophism (15-LOX), and amyloidogenesis (TSPAN12) (see
references in text); these up-regulated miRNAs and down-regulated mRNAs
form a highly integrated, pathogenic miRNA-mRNA signaling network
resulting in gene expression deficits in sporadic AD that may be
self-perpetuating due to chronic re-activation of NF-κB stimulation via IRAK-2
pathways (Cui et al., 2010; Lukiw, 2012a,b,c). Inhibition of the NF-κB initiator
or individual blocking of the pathogenic induction of these five miRNAs may
provide novel therapeutic approaches for the clinical management of AD,
however, what NF-κB or miRNA inhibition strategies, or whether they can be
utilized either alone or in combination, remain open to question. Preliminary
data has indicated that these approaches may neutralize this chronic,
inducible, progressive pathogenic gene expression program to re-establish
brain cell homeostasis, and ultimately be of novel pharmacological use in the
clinical management of AD.
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p65 subunit, to the proteasome-mediated
degradation of the IκB, to the translo-
cation of NF-κB to the nucleus, to the
prevention of NF-κB binding to DNA
recognition sites using decoy and/or anti-
sense strategies (Meffert and Baltimore,
2005; Gilmore and Herscovitch, 2006;
Nam, 2006; Yang et al., 2007; Gilmore
and Garbati, 2011; Lukiw et al., 2012).
Importantly, constitutive NF-κB signaling
is critically homeostatic to many aspects
of normal brain function, and essential
to the control of cell proliferation, apop-
tosis, innate, and adaptive immunity, the
inflammatory response and related stress
responses. NF-κB activation is also an
important part of a cellular recovery pro-
cess that may protect brain cells against
oxidative-stress or brain trauma-induced
apoptosis and induced neurodegenera-
tion, hence antagonism of NF-κB may
reduce its intrinsic potential for neuropro-
tective activity (Lukiw and Bazan, 1998;
Yang et al., 2007; Lukiw, 2012a,b,c). Since
NF-κB may have conflicting effects in
different brain cell types it is important
to assess anti-NF-κB (or anti-miRNA)
inhibition strategies in individual cell
types that constitute susceptible tissues.
For example, pro-inflammatory NF-κB-
sensitive miRNAs such as miRNA-146a
have been shown to be of varying basal
abundance, and be variably induced, in
different human primary brain and reti-
nal cell types (Alexandrov et al., 2011; Li
et al., 2011). Another interesting exam-
ple of interactive NF-κB and miRNA
effects are the differential regulation of the
interleukin-1 receptor associated kinases
IRAK-1 and IRAK-2 through NF-κB
actions (Cui et al., 2010; Flannery and
Bowie, 2010). In the regulation of IRAK-
1 expression, NF-κB has been shown to
induce miRNA-146a which, by virtue of
a miRNA-146a recognition feature in the
IRAK-1 3′-UTR, down-regulates IRAK-1
expression while at the same time activat-
ing transcription of IRAK-2, by virtue of
NF-κB binding in the IRAK-2 upstream
5′ regulatory region (Cui et al., 2010).
Importantly the IRAK-1 gene is devoid of
NF-κB recognition features in its 5′ regula-
tory region, while the IRAK-2 3′-UTR has
no recognition feature for miRNA-146a.
Hence anti-NF-κB strategies may affect
the pleiotrophic regulation of expression
of even highly homologous genes, such as
IRAK-1 and IRAK-2 that function in the
innate immune response, the sensing of
pathogens and the initiation of immunity.
An analogous example of the perceived
perils of wide-spectrum NF-κB inhibition
can be taken from neurooncology, and the
broad therapeutic strategies of using the
common alkylating anti-neoplastic drug
temozolamide (TMZ). TMZ attaches an
alkyl group to the guanine base of DNA,
resulting in base pair stabilization or cross-
linking, the inhibition of cell growth and
stimulation of apoptosis, and has been
widely used to treat glioblastoma and
other cancers (Thomas et al., 2013). As
the guanines of all genomic DNA are sus-
ceptible to alkylation, the use of TMZ is
tolerated because high rates of cell prolif-
eration renders cancer cells more sensitive
to alkyl modification. However, the gua-
nines of other cell DNAs that are natu-
rally rapidly dividing may also be alkylated
leading to off-target neurotoxic and neu-
rological effects (Lai et al., 2008; Nagasawa
et al., 2012; Thomas et al., 2013). Similarly,
global anti-NF-κB therapeutic strategies
may be more effective when NF-κB is
widely over stimulated in highly progres-
sive neuropathological situations such as
AD (Lukiw and Bazan, 1998; Yang et al.,
2007; Lukiw, 2013). Put another way,
NF-κB-inhibition strategies may be maxi-
mized only when NF-κB stimulated effects
have surpassed a critical threshold that are
en masse seriously detrimental to the nor-
mal homeostatic function of brain cells
and tissues. However, it is still problematic
and pharmacologically difficult to mini-
mize the complicating effects of NF-κB
inhibition on essential, low-level homeo-
static NF-κB function (Nam, 2006; Lukiw,
2012b).
On the other hand, anti-miRNA
(antagomir, AM) approaches are much
more target-efficient and a stabilized anti-
ribonucleotide, anti-miRNA sequence
100% homologous, and complementary
to the target miRNA will inhibit that tar-
get miRNA 95% or more with extremely
high efficacy (Lukiw et al., 2008; Cui et al.,
2010). Interestingly, tailoring imperfec-
tions into base-pair complementarity
between the anti-miRNA ribonucleotides
and the target miRNA could result in
partial inhibition of the miRNA with
a tailored “throttle-down” of miRNA-
mediated effects, and could be used as a
therapeutic strategy of “variable efficacy.”
It is clear that the appropriate clinical
application of these anti-NF-κB or anti-
miRNA strategies requires a more intimate
understanding of the specific NF-κB and
miRNA mechanisms responsible for their
activation pathway in different brain cell
types, definition of the optimal point of
intervention in the NF-κB or miRNA
activation pathway, and the characteri-
zation of potent and specific inhibitors
of the chosen NF-κB or miRNA targets.
Another formidable challenge lies in the
implementation of innovative anti-NF-κB
and anti-miRNA strategies without incur-
ring prohibitive off-target toxicity from
combinatorial approaches. Indeed, as has
been found from cancer research, rigor-
ous anti-NF-κB strategies may have long
term health consequences and appropriate
cautions should be exercised (Gilmore and
Herscovitch, 2006; Gilmore and Garbati,
2011; Nagasawa et al., 2012; Thomas et al.,
2013).
Lastly, virtually each day is now pro-
viding increased insight into the induc-
tion of NF-κB and miRNA in response
to physiological stressors, including the
mechanisms that regulate the bioavail-
ability of pro-inflammatory transcription
factors and miRNAs in immune health
and disease. The inducers of NF-κB also
appear to be the inducers of a highly
selective sub-family of NF-κB-sensitive
miRNAs (Lukiw, 2012a,b,c). These in
turn drive the expression of a char-
acteristic AD phenotype that includes
an up-regulation in inflammatory sig-
naling, amyloidogenesis, impairment in
microglial cell-mediated phagocytosis, and
deficits in synaptic and neurotrophic sig-
naling (Figure 1). Because NF-κB can vari-
ably regulate gene expression directly by
transcriptional activation and indirectly
by miRNA-mediated post-transcriptional
down-regulation it will be important to
further map out specific NF-κB-miRNA-
mRNA signaling pathways to ascertain at
what point anti-NF-κB or anti-miRNA-
based strategies may be best prescribed to
fit the individual pathological situation.
While NF-κB up-regulation helps define
a subset of inducible NF-κB-sensitive pre-
miRNA genes, there may be other tran-
scription factors, or combinations of tran-
scription factors that define the induction
of other small families of pre-miRNAs.
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Hence a general rule to follow may be
that a highly interactive network of NF-
κB or other transcription factor-sensitive
up-regulated miRNAs in stressed human
brain cells define an epigenetic expres-
sion program that is amenable to strategic
manipulation at some point, to eventually
normalize the dynamic balance between
inducible neurodegeneration or cell sur-
vival signals.
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